Key result
Lithium heparinate and EDTA validation for cardiac markers yields no reported results in the abstract.
Why the study?
Optimal performance of cardiac marker assays depends on overall turnaround time, including preanalytical sample preparation, with differences between serum and plasma concentrations needing validation.
Can lithium heparinate and EDTA plasma samples be used for valid cardiac marker determinations on the ACS:180 immunoassay system?
Can lithium heparinate and EDTA plasma samples be used for valid cardiac marker determinations on the ACS:180 immunoassay system?
This study aimed to validate the use of lithium heparinate and EDTA plasma samples for rapid cardiac marker testing on the ACS:180 immunoassay system to reduce preanalytical turnaround time.
No results reported; leaves open whether lithium heparinate or EDTA plasma suits cardiac marker testing on ACS:180.
The ACS:180® immunoassay system (Bayer Diagnostics) is an automated random analyzer that uses acridinium ester-based chemiluminescence detection. The architecture of the cardiac marker assays is a heterologous sandwich format, using monoclonal anti-marker antibody immobilized onto paramagnetic particles (capture) and polyclonal goat anti-human myoglobin, creatine kinase MB isoenzyme (CK-MB), or cardiac troponin I (cTnI) antibody labeled with acridinium ester (detector). Its processing time (∼20 min if the analyzer is in standby mode) and precision (overall CV <5%) make the system suitable for emergency use (1). However, optimal performance of an assay system for cardiac markers depends not only on the instrument’s analysis time, but also on factors that affect the overall turnaround time, including the preanalytical steps necessary to prepare the sample (2). The use of plasma samples eliminates the extra time needed for clotting, thereby reducing the overall preanalytical time, but there can be significant differences between serum and plasma concentrations of cardiac markers (3). The aim of this study was to validate the possible use of two different anticoagulants (lithium heparinate and EDTA, tripotassium salt) for cardiac marker determinations on the ACS:180 immunoassay system.
No takes yet. Share an insight, caveat, or question.
Pagani et al. (2000) studied this question. Lithium heparinate and EDTA anticoagulants vs. Serum was evaluated on Validation of anticoagulants for cardiac marker determinations. The study aimed to validate the use of lithium heparinate and EDTA anticoagulants for cardiac marker determinations on the ACS:180 immunoassay system, but no results were reported in the abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: